Organisation paid for research Program year 2025 Source: CMS Open Payments

Sante Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,157,185

282 payments

Through program year 2025, Sante Clinical Research is reported as receiving $1,157,185 in research payments, across 282 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$210,418	27
2024	Research	$388,902	89
2023	Research	$160,359	27
2022	Research	$456	2
2020	Research	$36,564	11
2019	Research	$360,487	126

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $365,603 139 payments
AstraZeneca Pharmaceuticals LP $204,013 11 payments
GlaxoSmithKline, LLC. $193,621 33 payments
Amgen Inc. $166,988 12 payments
Chiesi USA, Inc. $135,527 70 payments
AbbVie, Inc. $32,244 8 payments
Allergan Inc. $31,468 1 payment
Mylan Specialty L.P. $15,000 2 payments
Ionis Pharmaceuticals, Inc. $12,351 5 payments
Novartis Pharmaceuticals Corporation $370 1 payment

Studies the money was for Research payments · program years 2019–2025

Nn1250-4419 $258,725 115 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $82,736 5 payments
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $75,048 3 payments
Nn2211-4232 $67,856 11 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $59,889 35 payments
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Find $53,863 4 payments
ASTRO P3 AD Adolescent Mono $50,402 2 payments
A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian $43,531 8 payments
Nn1250-4252 $37,501 8 payments
STARLIGHT P2 LCM Asthma $35,001 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.